Friday Satellite Symposia
Friday, December 8

ASH would like to thank the participating sponsors of this year’s Friday Satellite Symposia. ASH views the Friday Satellite Symposia as a strong example of a healthy partnership between the Society and the corporate community, research-based companies, nonprofit organizations, and others who play an important role in providing meeting attendees with quality educational programs.

The following are confirmed Friday Satellite Symposia as of May 2006. These symposia are not part of the official 2006 ASH Annual Meeting, and an ASH badge is not needed to attend them. Each symposium is planned solely by the sponsoring organization, which will send detailed information and invitations prior to the meeting.

7:00 a.m. - 11:00 a.m.

Developments in the Treatment of Lymphoproliferative Disorders; Rising to the New Challenges of CLL Therapy
This program is sponsored by Discovery Institute of Medical Education and supported by Berlex Oncology.

7:00 a.m. - 11:00 a.m. • Peabody Orlando Hotel – Florida Room

Speakers:

• Michael Hallek, MD, University of Cologne, Cologne, Germany
• Susan O’Brien, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Steve Coutre, MD, Stanford University Medical Center, Stanford, CA
• Ben Kennedy, MRCPath, Leicester Royal Infirmary, Leicester, United Kingdom
• Thomas Lin, MD, PhD, The Ohio State University, Columbus, OH
• Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany

This symposium will highlight developments in the management of patients with CLL. Recent study data will be presented on risk stratification; treatment options for newly diagnosed, relapsed, and refractory patients; MRD assessment; and investigational, targeted therapies.

For more information, contact Rachael Benkert, Discovery Institute of Medical Education.

Phone: 312-553-8015
Fax: 312-553-8080
E-mail: rachael.benkert@dimeded.org

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Michael Hallek: research funding Roche, Amgen, and Ribosepharm; speakers bureau for Roche and Amgen.
• Dr. Susan O’Brien: research funding from Berlex, Genentech, and Biogen Idec.
• Dr. Steve Coutre: research funding from Novartis, Bristol-Myers Squibb, Avalon Pharmaceuticals, Cephalon, and Berlex.
• Dr. Ben Kennedy: consultant for Genzyme.
• Dr. Thomas Lin: research funding Amgen and Favrille; consultant to Berlex, Sanofi-Aventis, and Biogen Idec; and speakers bureau for Sanofi-Aventis.
• Dr. Stephan Stilgenbauer: research funding from Roche, Schering, Ribosepharm, Amgen Sanofi-Aventis, and Wyeth; consultant to Schering; speakers bureau for Roche, Schering, and Amgen; financial interest in Sanofi-Aventis.

Beyond T- and B-Cells: Exploring Innate Immunity
This program is sponsored by the University of Florida CME and supported by Enzon Pharmaceuticals.

7:00 a.m. - 11:00 a.m. • Rosen Plaza Hotel – Grand Ballroom C

Speakers:

• Elias Anaissie, MD, University of Arkansas for Medical Sciences, Little Rock, AR
• Douglas Golenbock, MD, University of Massachusetts Medical School, Worcester, MA
• Anne M. Dickinson, BSc, PhD, University of Newcastle, Newcastle upon Tyne, United Kingdom
• Stuart Levitz, MD, Boston Medical Center, Boston, MA
• John R. Wingard, MD, University of Florida Health Science Center, College of Medicine, Gainesville, FL

This symposium will aid participants in their ability to integrate their knowledge of innate immunity into clinical practice in order to identify defects of this limb of the system and obtain knowledge of current and future interventions that can improve outcomes in individual immunocompromised patients.

For more information, contact Liz Etler, The MedEd Group LLC.

Phone: 973-951-2030
Fax: 973-847-5624
E-mail: ejalter@comcast.net

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Elias Anaissie: grant/research support from Pfizer, Amgen, Astellas, Ortho Biotech and CuraGen; consultant for Pfizer, Amgen, Astellas, and Gilead Sciences; and speakers bureau member for Pfizer, Amgen, Astellas, Gilead Sciences, Merck, and Schering-Plough.
• Dr. Douglas Golenbock: grant/research support from NIH and a consultant for Eisai Research Institute.
• Dr. Anne M. Dickinson indicated no conflicts of interest.
• Dr. Stuart Levitz indicated no conflicts of interest.
• Dr. John R. Wingard: research support from, and a consultant and speakers bureau member for, Pfizer and Merck; also a consultant for Schering and Vical.

Bridging the Gap Between Promise and Practice – Moving Toward a Cure in Follicular Lymphoma
This program is sponsored by the Medical Education Collaborative and supported by Medical Communication and Research Inc. (MCRI).

7:00 a.m. - 11:00 a.m. • Rosen Centre Hotel – Grand Ballroom D-E

Speakers:

• James Armitage, MD, University of Nebraska College of Medicine, Omaha, NE
• Robert Dillman, MD, Hoag Cancer Center, Newport Beach, CA
• Stephen Ansell, MD, Mayo Clinic, Rochester, MN
• Andrew Zelenetz, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
• Oliver Press, MD, PhD, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA
• Brad Pohlman, MD, Cleveland Clinic Foundation, Cleveland, OH
• Timothy Illidge, MD, PhD, Paterson Institute and Christie Hospital at Manchester University, Manchester, United Kingdom
• Ian Flinn, MD, PhD, Sarah Cannon Research Institute, Nashville, TN
• Christian Gisselbrecht, MD, Institut d' Hématologie, Hospital St. Louis, Paris, France

This scientifically detailed, clinically intense, and truly novel educational meeting will raise, discuss, and analyze some of the most significant controversies in lymphoma care.

For more information, contact Jaye Harden, Network for Medical Communication and Research.

Phone: 404-845-3771
Fax: 404-252-9869
E-mail: jharden@nmcr.com

Speaker Disclosures
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. James Armitage: honoraria from Amgen, Biogen Idec, and GlaxoSmithKline; consultant for Celgene, Genitope, and GlaxoSmithKline.
• Dr. Robert Dillman: stock ownership in Abbott, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Johnson and Johnson, Pfizer, and Schering-Plough; consultant for Amgen, Biogen Idec, and Genentech; research support from Biogen Idec, CancerVax, NovaRx, and SuperGen; speakers bureau member for Biogen Idec, Chiron, Genentech Sanofi-Aventis, and SuperGen; paid committee member for Genitope and Onyx; advisory board for Arius.
• Dr. Stephen Ansell: research support from ZymoGenetics.
• Dr. Andrew Zelenetz: paid research for Biogen Idec, GlaxoSmithKline, Amgen, and Genentech; speakers bureau for GlaxoSmithKline.
• Dr. Oliver Press: advisory committee member for Celgene and Cell Therapeutics.
• Dr. Brad Pohlman: speakers bureau for Amgen, Biogen Idec, and Genentech.
• Dr. Timothy Illidge: advisory committee for Biogen Idec; consultant for GlaxoSmithKline; consultant and speakers bureau member for Schering AG.
• Dr. Ian Flinn: paid research for Amgen, Biogen Idec, Genentech, and Genitope.
• Dr. Gisselbrecht: advisory committee of Hoffmann-La Roche, Millennium Pharmaceuticals, Ortho Biotech, and Wyeth Pharmaceuticals; paid research for Hoffmann-La Roche, Ortho Biotech, Wyeth Pharmaceuticals, and Schering AG; speakers bureau for Schering AG.

The Therapeutic Potential of Epigenetics in MDS and AML
This program is sponsored by The University of Texas M.D. Anderson Cancer Center and supported by MGI Pharma Inc.

7:00 a.m. - 11:00 a.m. • Rosen Plaza Hotel – Grand Ballroom A

Speakers:

• Jean-Pierre Issa, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Peter Jones, MD, Keck School of Medicine, Los Angeles, CA
• Carlos Manuel de Castro, MD, Duke University Medical Center, Durham, NC
• Pierre Wijermans, MD, PhD, Hospital Leyenburg, The Hague, Netherlands
• Frederick Appelbaum, MD, Fred Hutchinson Cancer Research Center, Seattle, WA

This symposium will cover the development of DNA methyltransferase inhibitors for the treatment of hematologic malignancies. Particular attention will be given to the clinical impact of hypomethylating agents on MDS and AML, diseases that have a poor prognosis and are more common in elderly patients who are ineligible for intensive chemotherapy. Application of the knowledge from recent studies to the wider clinical setting to optimize the future clinical impact of these agents will be discussed.

For more information, contact Janet Walsh, Darwin Grey Communications.

Phone: 44-1865-822-555
Fax: 44 -1865-822-550
E-mail: janet.walsh@darwingrey.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Jean-Pierre Issa: grant/research support and honoraria from MGI Pharma and Pharmion; speakers bureau for MGI Pharma and Pharmion; consultant for MGI Pharma and Celgene.
• Dr. Peter Jones: consultant to, and has ownership interest in, Epigenomics AG; speakers bureau for MGI Pharma.
• Dr. Carlos Manuel de Castro: speakers bureau member for Celgene, Pharmion, MGI Pharma; advisory board member for Alexion, MGI Pharma, and Celgene.
• Dr. Pierre Wijermans indicated no conflicts of interest.
• Dr. Frederick Appelbaum: grant/research support from Kanisa; consultant for Wyeth; speakers bureau member for Bristol-Myers Squibb; employee of Merck; honoraria from Vion; advisory board member for Genzyme; and ownership interest in ZymoGenetics.

Unanswered Questions and Clinical Considerations in the Treatment of Multiple Myeloma and Lymphomas
This program is sponsored by the Center for Biomedical Continuing Education (CBCE) and supported by Millennium Pharmaceuticals.

7:00 a.m. - 11:00 a.m. • Orange County Convention Center – Valencia A-B

Speakers:

• Sundar Jagannath, MD, St. Vincent’s Comprehensive Cancer Center, New York, NY
• Sergio Giralt, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Andre Goy, MD, The Cancer Center at Hackensack University Medical Center, Hackensack, NJ
• Martin Dreyling, MD, PhD, University of Munich, Munich, Germany
• Jorge Romaguera, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX 

This program will provide participants with an update on the latest targeted therapies and their impact on patients with multiple myeloma and low-grade lymphomas.

For more information, contact Christa Dardaganian, Cadent Medical Communications.

Phone: 972-692-2025
Fax: 972-929-1901
E-mail: cdardaganian@cadentmed.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Sundar Jagannath: speakers bureau for Celgene and Millennium Pharmaceuticals
• Dr. Sergio Giralt: honoraria from Celgene, Cephalon, and Millennium Pharmaceuticals.
• Dr. Andre Goy indicated no conflicts of interest.
• Dr. Martin Dreyling: honoraria from Roche, Schering, and Millennium Pharmaceuticals; consultant for Millennium Pharmaceuticals; contracted research for Roche, Schering, and Ortho Biotech.
• Dr. Jorge Romaguera: honoraria from Roche; contracted research for Wyeth and Celgene.

Paradigms in MDS Prognosis and Treatment
This program is sponsored by Educational Review Systems and supported by Myelodysplastic Syndromes Foundation Inc.

7:00 a.m. - 11:00 a.m. • Orange County Convention Center – Hall WF 3, 4, 5

Speakers:

• John Bennett, MD, University of Rochester, Rochester, NY
• Detlef Haase, MD, Georg-August-Universitat, Göttingen, Germany
• Alan F. List, MD, H. Lee Moffitt Cancer Center, Tampa, FL
• Michael Lubbert, MD, PhD, University of Freiburg, Freiburg, Germany
• Luca Malcovati, MD, University of Pavia Medical School, Pavia, Italy

This symposium will focus on evolving morphologic and response assessment criteria, the impact of clonal karyotypic abnormalities, and acquisition of new abnormal karyotypes (including lesser known genetic abnormalities) as they relate to disease progression, implications of current molecular genetic research on therapeutic targeting of the epigenome, the effect of transfusion-dependence and chelation therapy on prognosis, and the need for targeting, monitoring, and evaluating therapeutic interventions based on disease stability or progression.

For more information, contact Susan Hogan, KMH Medical Communications.

Phone: 609-298-0342
Fax: 609-298-0590
E-mail: shogan@kmhmedical.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. John Bennett: grant/research support and honoraria from Celgene and Pharmion.
• Dr. Detlef Haase indicated no conflicts of interest.
• Dr. Alan F. List: grants/research support from Scios; consultant for Celgene, Pharmion, and Scios; honoraria from Celgene and Pharmion; other financial/material support from Schering and Kanisa.
• Dr. Michael Lubbert: honoraria and other support from, and a consultant for, MGI Pharma.
• Dr. Luca Malcovati indicated no conflicts of interest.

Hemostatic Challenges in Cancer
This program is sponsored by American Academy of CME Inc. and supported by Novo Nordisk.

7:00 a.m. - 11:00 a.m. • Orange County Convention Center – Room 330 D-G

Speakers:

• Nigel Key, MD, University of North Carolina School of Medicine, Chapel Hill, NC
• Don A. Gabriel, MD, PhD, University of North Carolina School of Medicine, Chapel Hill, NC
• Nancy Marie Heddle, MSc, FCMLS, McMaster University, Hamilton, Ontario, Canada

Considerable variability exists in the types of bleeding that occur in patients with malignancies. Controversies regarding the prevention and treatment of bleeding complications and the underlying causes and clinical consequences of such complications are gaining increasing attention. This symposium will provide an overview of bleeding complications in patients with cancer and the challenges associated with their management.

For more information, contact Jennifer Kelly, Acumentis.

Phone: 215-412-5950
Fax: 215-412-0205
E-mail: jennifer.kelly@acumentis.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Nigel Key: consultant for Novo Nordisk, Baxter, and Grifols..
• Dr. Don A. Gabriel: speaker for Talecris, Novo Nordisk, Reliant Pharmaceuticals, Millennium Pharmaceuticals, and InVitrox.
• Dr. Nancy Marie Heddle indicated no conflicts of interest.

The Promise of Epigenetic Therapy
This program is sponsored by Current Therapeutics Inc. and supported by Pharmion Corporation.

7:00 a.m. - 11:00 a.m. • Peabody Orlando Hotel – Orlando Room

Speakers:

• Stephen B. Baylin, MD, Johns Hopkins School of Medicine, Baltimore, MD
• Allen S. Yang, MD, PhD, University of Southern California, Keck School of Medicine,
• Los Angeles, CA
• Steven Grant, MD, Virginia Commonwealth University Health System, Richmond, VA
• Guillermo Garcia-Manero, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Steven D. Gore, MD, Johns Hopkins School of Medicine, Baltimore, MD

The use of epigenetic targets is emerging as a feasible approach to cancer therapy. This symposium will elucidate the mechanisms and clinical applications of two such groups of drugs: DNA methylation inhibitors and histone deacetylase (HDAC) inhibitors. Both classes of drugs target aberrantly silenced genes, leading to reactivation of tumor-suppressor genes and other genes necessary for normal cell function. The implications for cancer therapy include novel combinations of epigenetic drugs as well as epigenetic drugs in combination with other therapies.

For more information, contact Kristi Thomsen, Current Therapeutics Inc.

Phone: 216-464-6240
Fax: 216-464-6364
E-mail: kristi@currentrx.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Stephen Baylin: grants/research support from NIH, NCI, NIEHS, DOD, the Susan G. Komen Breast Cancer Foundation, the Samuel Waxman Cancer Research Foundation, OncoMethylome Sciences, and BioNumerik Pharmaceuticals Inc.
• Dr. Allen Young: grants/research support from MethylGene; consultant for MGI Pharma and Pharmion.
• Dr. Steven Grant: grants/research support from NIH and DOD.
• Dr. Guillermo Garcia-Manero: grants/research support and honoraria from MGI Pharma and Pharmion.
• Dr. Steven Gore: consultant for Celgene and Pharmion.

Development of an Oral Xa Inhibitor: Rationale and Initial Clinical Results
This program is sponsored by McMaster University and supported by Scios and Bayer Healthcare.

7:00 a.m. - 11:00 a.m. • Rosen Centre Hotel – Grand Ballroom A-B

Speakers:

• Jack Hirsh, MD, McMaster University, Hamilton, Ontario, Canada
• Ken Bauer, MD, Beth Israel Deaconess Medical Center, Boston, MA
• Jack Ansell, MD, Boston University Medical Center, Boston, MA
• Charles Esmon, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK
• Giancarlo Agnelli, MD, Università di Perugia, Perugia, Italy
• Alexander G.G. Turpie, MB, ChB, FACC, McMaster University, Hamilton, Ontario, Canada

Current anticoagulants have limitations that have prompted the development of new anticoagulants. This program will focus on the mechanisms of action of new anticoagulants including those that directly and indirectly target Factor Xa.

For more information, contact Barbara Mitros, Center for Healthcare Education.

Phone: 858-345-1156
Fax: 858-345-1153
E-mail: bmitros@tier1group.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Jack Hirsh indicated no conflicts of interest.
• Dr. Ken Bauer: consultant to Bayer and GlaxoSmithKline; speakers bureau for GlaxoSmithKline.
• Dr. Jack Ansell: grant/research support from Boehringer-Ingelheim and Ocean Spray; consultant to Bayer, Novartis, Bristol-Myers Squibb, Roche Diagnostics, St. Jude Medical, and Regado; speakers bureau for Bristol-Myers Squibb and Sanofi-Aventis.
• Dr. Charles Esmon indicated no conflicts of interest.
• Dr. Giancarlo Agnelli indicated no conflicts of interest.
• Dr. Alexander G.G. Turpie: consultant to Bayer, Sanofi-Aventis, and GlaxoSmithKline; speakers bureau for Sanofi-Aventis, Pfizer, and GlaxoSmithKline.

12:30 p.m. - 4:30 p.m.

The Biology of Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria:
Impact on Diagnosis, Management, and Emerging Therapies
This program is sponsored Thomson Professional Postgraduate Services^® and supported by
Alexion Pharmaceuticals, Inc.

12:30 p.m. – 4:30 p.m. • Orange County Convention Center – Room 311

Speakers:

• Peter Hillmen, MD, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
• Neal S. Young, MD, National Institutes of Health/National Heart, Lung and Blood
  Institute, Bethesda, Maryland
• Edward Gordon-Smith, MD, St. George’s Hospital, London, United Kingdom
• Taroh Kinoshita, PhD, Osaka University, Osaka, Japan
• Monica Bessler, MD, PhD, Washington University School of Medicine, St. Louis, MO

Aplastic anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) are rare clonal disorders that few clinicians have had experience in treating. Recent advances have resulted in the development of promising new therapies hoping to give clinicians new options to manage these disorders. This symposium will help hematologists and hemato-oncologists understand the etiology, clinical manifestations, and diagnostic testing for AA and PNH, so they may utilize the most effective management options for their high-risk patients.

For more information, contact Brenda Feldman, Thomson Professional Postgraduate Services^®.

Phone: 201-271-6135
Fax: 201-430-1135
E-mail: brenda.feldman@pps.thomson.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Peter Hillmen: research support for Alexion Pharmaceuticals Inc.
• Dr. Neal S. Young indicated no conflicts of interest.
• Dr. Edward Gordon-Smith indicated no conflicts of interest.
• Dr. Taroh Kinoshita indicated no conflicts of interest.
• Dr. Monica Bessler: research support from Celgene Corporation; also a consultant and stockholder for Alexion Pharmaceuticals.

Thrombocytopenia in the Practice of Hematology and Oncology
This program is sponsored by Curatio CME Institute LLC and supported by Amgen Inc.

12:30 p.m. - 4:30 p.m. • Rosen Centre Hotel – Grand Ballroom A-B

Speakers:

• David J. Kuter, MD, DPhil, Massachusetts General Hospital, Boston, MA
• Victor Blanchette, FRCP, Hospital for Sick Children, Toronto, Ontario, Canada
• James N. George, MD, University of Oklahoma Health Sciences Center, Oklahoma City, OK
• David P. Steensma, MD, Mayo Clinic, Rochester, MN

The management of patients with thrombocytopenias is common and is increasing in frequency in the hematology/oncology practice. Critical questions frequently encountered include: how best to comprehend the clinical complexity of congenital inherited thrombocytopenias; what are the physiologic and etiologic bases for idiopathic thrombocytopenic purpura (ITP); how to best treat chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenic states associated with ineffective hematopoiesis, such as myelodyplastic syndromes (MDS); and what are the emerging therapies for thrombocytopenia. This program will provide physicians with new data and treatment strategies for managing thrombocytopenias in their hematology/oncology practice, with the aim of improving patient outcomes and quality of life.

For more information, contact Kristen Petro, Curatio CME Institute LLC.

Phone: 610-363-1619, ext. 115
Fax: 610-363-7410
E-mail: kristen.petro@curatiocme.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. David J. Kuter: research support from, and a consultant for Amgen; also a consultant for GlaxoSmithKline and AkaRx.
• Dr. Victor Blanchette: honoraria from Baxter BioScience Corporation, Bayer Corporation, Wyeth, and ZLB-Behring.
• Dr. James N. George: research support from, and a consultant for, Amgen.
• Dr. David P. Steensma indicated no conflicts of interest.

Targeting Chemokines in Hematologic Malignancies and Bone Marrow Transplants
This program is sponsored by Physicians Education Resource and supported by AnorMed Inc.

12:30 p.m. - 4:30 p.m. • Peabody Orlando Hotel – Orlando Room

Speakers:

• David Dale, MD, University of Washington, Seattle, WA
• Patrick Stiff, MD, Loyola University Medical Center, Chicago, IL
• Neal Flomenberg, MD, Thomas Jefferson University, Philadelphia, PA
• Richard Childs, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
• John DiPersio, MD, PhD, Washington University, St. Louis, MO
• Richard Champlin, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Steven M. Devine, MD, The Ohio State University, Columbus, OH

The purpose of this symposium is to meet the need of physicians to more adequately understand how the CXCR4 pathway can be manipulated to the therapeutic benefit of patients undergoing transplant, as well as to look to the future of what this pathway may mean in terms of chemosensitization and inhibition of metastasis.

For more information, contact Susanne Blassingille, Physicians Education Resource.

Phone: 214-367-3481
Fax: 214-367-3303
E-mail: sus.blassingille@pergrouplp.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. David Dale: on the advisory board of, and has stock holdings with, AnorMED.
• Dr. Patrick Stiff: research funding from AnorMED.
• Dr. Neal Flomenberg indicated no conflicts of interest.
• Dr. Richard Childs indicated no conflicts of interest.
• Dr. John DiPersio indicated no conflicts of interest.
• Dr. Richard Champlin: consultant to Genzyme, AnorMED, and Amgen.
• Dr. Steven M. Devine: research funding from AnorMED.

Eighth Annual Review of Immune Thrombocytopenic Purpura; ITP Guidelines
This program is sponsored by Weill Medical College of Cornell University and supported by Baxter Healthcare Corporation.

12:30 p.m. - 4:30 p.m. • Rosen Centre Hotel – Grand Ballroom D-E

Speakers:

• Robert McMillan, MD, The Scripps Research Institute, La Jolla, CA
• Douglas Cines, MD, University of Pennsylvania School of Medicine, Philadelphia, PA
• Patrick Fogarty, MD, University of California - San Francisco, San Francisco, CA
• Terry Gernsheimer, MD, University of Washington School of Medicine, Seattle, WA
• Keith McCrae, MD, Case Western Reserve University School of Medicine, Cleveland, OH
• Michael Tarantino, MD, University of Illinois College of Medicine at Peoria, Peoria, IL
• James Bussel, MD, Weill Medical College of Cornell University, New York, NY
• Bertrand Godeau, MD, Hôpital Henri Mondor, Paris, France
• Howard Liebman, MD, University of Southern California, Keck School of Medicine, Los Angeles, CA
• Roberto Stasi, MD, Regina Apostolorum Hospital, Albano Laziale, Italy
• Amy Geddis, MD, PhD, University of California – San Diego, La Jolla, CA
• Carlo Balduini, MD, IRCCS Policlinico San Matteo, Pavia, Italy
• Paula Bolton-Maggs, BMBch, Manchester Royal Infirmary, Manchester Haemophilia Comprehensive Care Center, Manchester, United Kingdom
• Jodi Segal, MD, Johns Hopkins University School of Medicine, Baltimore, MD

This symposium will discuss past, present, and future guidelines for immune thrombocytopenic purpura (ITP), including ITP in children and adults, pregnancy, and secondary and non-immune ITP. The symposium will provide an update on the diagnostic and treatment strategies for patients with primary or secondary ITP.

For more information, contact Robin Simak, Jonathan Wood and Associates.

Phone: 201-594-0400
Fax: 201-594-0409
E-mail: rsimak@jwoodassoc.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Robert McMillan indicated no conflicts of interest.
• Dr. Douglas Cines: consultant for Baxter Healthcare Corporation, Amgen, GlaxoSmithKline, ZLB Behring, Talecris, Biovitrium, Fujisawa, and Genentech.
• Dr. Patrick Fogarty indicated no conflicts of interest.
• Dr. Terry Gernsheimer: honoraria from, and a consultant and speakers bureau member for, Baxter Healthcare Corporation.
• Dr. Keith McCrae: honoraria from Baxter Healthcare Corporation and Amgen.
• Dr. Michael Tarantino: research support from Baxter Biopharmaceuticals; consultant for Baxter Bioscience; speakers bureau member for Baxter Bioscience and Novo Nordisk.
• Dr. James Bussel: research support from Amgen, Baxter Healthcare Corporation, Biogen Idec, Cangene, Genentech, GlaxoSmithKline, and Sysmex; speakers bureau member for Baxter Healthcare Corporation.
• Dr. Bertrand Godeau indicated no conflicts of interest.
• Dr. Howard Liebman: consultant for Baxter Healthcare Corporation.
• Dr. Roberto Stasi indicated no conflicts of interest.
• Dr. Amy Geddis indicated no conflicts of interest.
• Dr. Carlo Balduini indicated no conflicts of interest.
• Dr. Paula Bolton-Maggs: honorarium from Diagnostico Stago.
• Dr. Jodi Segal indicated no conflicts of interest.

Clinical Challenges and Unmet Needs in Anticoagulant Therapy
This program is sponsored by Imedex Inc. and supported by Boehringer Ingelheim Pharmaceuticals Inc.

12:30 p.m. - 4:30 p.m. • Peabody Orlando Hotel – Florida Room

Speakers:

• Jeffrey I. Weitz, MD, McMaster University, Hamilton, Ontario, Canada
• Samuel Z. Goldhaber, MD, Harvard Medical School, Boston, MA
• Gary E. Raskob, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK

This CME program will address the history, current state, and ongoing research in the area of anticoagulant therapy. Leading experts in the field will present and discuss topics including risk stratification, prophylaxis, and potential future therapeutic advances. This symposium will include didactic and interactive sessions.

For more information, contact Jonathan Countess, Imedex Inc.

Phone: 770-751-7332
Fax: 770-751-7334
E-mail: j.countess@imedex.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Jeffrey I. Weitz: consultant for Boehringer-Ingelheim, AstraZeneca, The Medicines Company, Bayer, Bristol-Myers Squibb, and Daiichi.
• Dr. Samuel Z. Goldhaber: grant/research support from Sanofi-Aventis and GlaxoSmithKline; consultant for Sanofi-Aventis, Bristol-Myers Squibb, Boehringer-Ingelheim, and Emisphere Technologies.
• Dr. Gary E. Raskob: consultant for Boehringer-Ingelheim, Bayer, Bristol-Myers Squibb, Sanofi-Aventis, Daiichi, and GlaxoSmithKline; speakers bureau for GlaxoSmithKline and Sanofi-Aventis.

Immunomodulation: Assessing the Science in Hematologic Malignancies
This program is sponsored by the Medical Education Collaborative and supported by Celgene Corporation.

12:30 p.m. - 4:30 p.m. • Orange County Convention Center – Hall WF 3, 4, 5

Speakers:

• Clara Bloomfield, MD, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH
• Rafael Fonseca, MD, Mayo Clinic Scottsdale, Scottsdale, AZ
• Keith Stewart, MD, Mayo Clinic Scottsdale, Scottsdale, AZ
• Peter Wiernik, MD, Our Lady of Mercy Cancer Center, Bronx, NY
• Mikkael Sekeres, MD, The Cleveland Clinic Foundation, Cleveland, OH
• Alessandra Ferrajoli, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX

This symposium will use a combination of didactic presentations of data in conjunction with patient case scenarios to elicit the most interactive discussion and learning environment. World-renowned thought leaders will discuss patient case scenarios and data supporting various treatment strategies with the goal of providing the most thorough analysis of all currently available and emerging data. The agenda and meeting design will optimize the discussion between the faculty and audience. All of these components will result in a multi-faceted approach to how new data should fit into current hematology practice.

For more information, contact Jaye Harden, the American School of Oncology.

Phone: 404-845-3771
Fax: 404-252-9869
E-mail: jharden@nmcr.com

Speaker Disclosures
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Clara Bloomfield indicated no conflicts of interest.
• Dr. Rafael Fonseca: consultant to Centocor Inc., Millennium Pharmaceuticals, and Celgene; paid research for Pfizer.
• Dr. Keith Stewart: stock ownership in Celgene and Millennium Pharmaceuticals; consultant and advisory committee member for Celgene, Millennium Pharmaceuticals, and Ortho Biotech; consultant for Novartis.
• Dr. Peter Wiernik: paid research for Bayer, Celgene, Genentech, and Pfizer; consultant and advisory committee member for Celgene; speakers bureau for Pfizer.
• Dr. Mikkael Sekeres: speakers bureau for Celgene, Pharmion, and Cell Therapeutics; paid research for Celgene
• Dr. Alessandra Ferrajoli indicated no conflicts of interest.

The Experts Debate Current Treatment of B-Cell Malignancies
This program is sponsored by the Center for Biomedical Continuing Education (CBCE) and supported by Genentech BioOncology and Biogen Idec.

12:30 p.m. - 4:30 p.m. • Orange County Convention Center – Valencia A-B

Speakers:

• David C. Linch, FRCP, FMedSci, University College of London, London, United Kingdom
• Wolfgang Hiddemann, MD, PhD, Ludwig-Maximilians University, Munich, Germany
• David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA
• Robert Marcus, MD, Addenbrooke’s Hospital, Cambridge, United Kingdom
• Michael Pfreundschuh, MD, PhD, University of Saarland, Homburg, Germany
• Joseph M. Connors, MD, University of British Columbia, Vancouver, British Columbia, Canada
• Julie M. Vose, MD, University of Nebraska Medical Center, Omaha, NE
• Richard I. Fisher, MD, University of Rochester Medical Center, Rochester, NY
• John C. Byrd, MD, The Ohio State University, Columbus, OH
• John G. Gribben, MD, DSc, Barts Hospital, London, United Kingdom
• Sandra J. Horning, MD, Stanford University School of Medicine, Stanford, CA

This program will discuss the safety and efficacy of dose-dense combination regimens for the treatment of elderly patients with B-cell lymphoma. This symposium will assess the role of autologous stem cell transplantation and high-dose consolidation therapy in younger patients with high-risk lymphoma. It will also evaluate recent data on the use of molecular prognostic and predictive markers in determining the course of therapy for patients with CLL.

For more information, contact Donna Morin, Center for Biomedical Continuing Education (CBCE).

Phone: 972-692-2042
Fax: 214-260-0408
E-mail: dmorin@thecbce.com

Speaker Disclosures
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. David Linch: consultant to Roche and Chugai; honoraria from Roche and Amgen.
• Dr. Wolfgang Hiddemann: honoraria from Roche International, Basel.
• Dr. David Maloney: consultant to Biogen Idec and Genentech; contracted research for Genentech.
• Dr. Robert Marcus: consultant to Roche and Genentech.
• Dr. Michael Pfreundschuh: consultant to Roche and Genentech.
• Dr. Joseph Connors: honoraria from Roche Canada and Genentech; contracted research with Roche Canada.
• Dr. Julie Vose: grant/research support from Genentech, Biogen Idec, GlaxoSmithKline, Millennium Pharmaceuticals, Boehringer-Ingelheim, Wyeth, Celgene, AnorMED, and Genitope.
• Dr. Richard Fisher: honoraria and consulting fees from Genentech and GlaxoSmithKline.
• Dr. John Byrd: contracted research with Biogen Idec, Berlex, and Pfizer; ownership interest in Pharmion; and intellectual property rights from Sanofi-Aventis and Abbott Laboratories.
• Dr. John Gribben: consultant for Biogen Idec, Amgen, Roche, and Schering AG.
• Dr. Sandra Horning: consultant to Genentech and honoraria from Roche.

Defining Therapeutic and Diagnostic Advances in the Management of AML
This program is sponsored by Meniscus Educational Institute and supported by Genzyme Corporation.

12:30 p.m. - 4:30 p.m. • Orange County Convention Center – Room 414 A-B

Speakers:

• Stephen Nimer, Memorial Sloan-Kettering Cancer Center, New York, NY
• Stefan H. Faderl, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA
• Martin Tallman, MD, Northwestern University Cancer Center, Chicago, IL
• Jacob M. Rowe, MD, Rambam Medical Center, Haifa, Israel

This interactive symposium will include evidence-based discussions of the advances in the diagnosis and management of AML. It will address the correlation of molecular lesions to treatment approaches, new agents, appropriate clinical trial design, and the challenges of managing AML in the elderly and those with antecedent hematologic disorders and allogeneic bone marrow transplantation.

For more information, contact Rebecca Finley, Meniscus Educational Institute.

Phone: 610-834-1810
Fax: 610-834-8856
E-mail: rfinley@meniscus.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Stephen Nimer indicated no conflicts of interest.
• Dr. Stefan H. Faderl: grant/research support from, and a consultant for, Genzyme.
• Dr. Richard Stone: consultant/advisory board member to Genzyme, Bristol-Myers Squibb and Hana Biosciences; lecture fees from Pharmion, Novartis, Amgen, and Celgene; research support from Novartis and Bristol-Myers Squibb.
• Dr. Martin Tallman: consultant/advisory board member to Genzyme
• Dr. Jacob M. Rowe indicated no conflicts of interest.

Genetic Factors in the Predisposition, Pathogenesis, and Treatment of the Hematologic Malignancies
This program is sponsored by the University of Rochester School of Medicine and Dentistry, Office of Professional Education, and supported by the Leukemia and Lymphoma Society.

12:30 p.m. - 4:30 p.m. • Orange County Convention Center – Room 224 A-B-E-F

Speakers:

• Alan D. D’Andrea, MD, Harvard Medical School, Boston, MA
• Marshall Horwitz, MD, PhD, University of Washington School of Medicine, Seattle, WA
• Carlo Croce, MD, The Ohio State Comprehensive Cancer Center, Columbus, OH
• William E. Evans, PharmD, St. Jude Children’s Research Hospital, Memphis, TN
• Leslie Robinson, PhD, St. Jude Children’s Research Hospital, Memphis, TN

This symposium will encompass new approaches to the diagnosis, treatment, and prognosis of leukemia, lymphoma, and myeloma (blood-related cancers), including advances in specific genetic modifications that: a) predispose to the onset of these diseases as a result of DNA repair abnormalities; b) account for uncommon familial clustering of these diseases; c) determine the increasing importance of microRNA in the pathogenesis of the hematologic malignancies; d) result in polymorphisms that influence therapeutic effects of drugs used in treatment; and e) explain exaggerated deleterious late effects after treatment in some patients. It is important and timely to acquaint physicians and scientists with the new understanding of genetic alterations that predispose to the disease or polymorphic modifications in genes that influence the response to therapy in patients treated for hematologic malignancies.

For more information, contact Allyson Bodin O’Connor, Leukemia and Lymphoma Society.

Phone: 914-821-8838
Fax: 914-821-3638
E-mail: bodina@lls.org

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Alan D'Andrea indicated no conflicts of interest.
• Dr. Marshall Horwitz indicated no conflicts of interest.
• Dr. Carlo M. Croce indicated no conflicts of interest.
• Dr. William E. Evans indicated no conflicts of interest.
• Dr. Leslie L. Robinson indicated no conflicts of interest.

Targeting T Cells: New Paradigms in the Treatment of Lymphoproliferative Disorders and Transplantation
This program is sponsored by Vindico Medical Education and supported by MedImmune Inc.

12:30 p.m. - 4:30 p.m. • Rosen Centre Hotel – Salon 9-10

Speakers:

• Francine Foss, MD, Yale University, New Haven, CT
• Randy Gascoyne, MD, FRCPC, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
• Thomas Waldmann, MD, National Cancer Institute, Bethesda, MD
• John Janik, MD, National Cancer Institute, Bethesda, MD
• Thomas Spitzer, MD, Harvard University, Cambridge, MA
• Megan Sykes, MD, Harvard University, Cambridge, MA

This symposium will identify clinical applications and current research of MAb therapies and recognize the need for ongoing research. Non-Hodgkin lymphoma (NHL) is the sixth most common cause of death in the United States. This symposium will define the clinical application of CD2-mediated T-cell depletion in the treatment of NHL.

For more information, contact Stephanie Tallman, Vindico Medical Education.

Phone: 856-994-9400, ext. 397
Fax: 856-384-6680
E-mail: stallman@vindicomeded.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Francine Foss indicated no conflicts of interest.
• Dr. Randy Gascoyne indicated no conflicts of interest.
• Dr. Thomas Waldmann: research funding from MedImmune.
• Dr. John Janik: research funding from MedImmune.
• Dr. Thomas Spitzer indicated no conflicts of interest.
• Dr. Megan Sykes indicated no conflicts of interest.

Cell Therapy: Present and Future
This program is sponsored by the Medical Education Collaborative and supported by Miltenyi Biotec GmbH.

12:30 p.m. - 4:30 p.m. • Rosen Plaza Hotel – Grand Ballroom C

Speakers:

• Robert Hawkins, MD, Paterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom
• Nicolaus Kröger, MD, University Hospital Hamburg-Eppendorf, Hamburg, Germany
• Gregory Hale, MD, St. Jude Children’s Research Hospital, Memphis, TN
• Vincent Ho, MD, Dana-Farber Cancer Institute, Boston, MA
• J.H. Frederik Falkenburg, MD, PhD, Leiden University Medical Center, Leiden, Netherlands
• Gustav Steinhoff, MD, University of Rostock, Rostock, Germany
• Ann Jakubowski, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY

New strategies for cellular therapy will be presented. The applications include hematologic or viral diseases and cardiovascular diseases. The goal is an improvement of disease management and quality of life of patients.

For more information, contact Jenn Charlebois, Malachite Management Inc.

Phone: 604-874-4004
Fax: 604-874-4378
E-mail: jenn@malachite-mgmt.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Robert Hawkins: research support, and a speakers bureau member for, Chiron; research support from Chugai, Miltenyi Biotec, and Pfizer; and a consultant for GlaxoSmithKline, Oxford Biomedica, Orion Clinical Services, Oxxon Therapeutics, Bayer, and Pfizer.
• Dr. Nicolaus Kröger: research support from Fresenius Biotech and Chugai.
• Dr. Gregory Hale: advisory board member for Noxafil.
• Dr. Vincent Hoindicated no conflicts of interest.
• Dr. J.H. Frederik Falkenburg indicated no conflicts of interest.
• Dr. Gustav Steinhoff: shared research support with Miltenyi Biotec.
• Dr. Ann Jakubowski indicated no conflicts of interest.

Post-Transplant Patient Care: Tailored Prevention and Management Strategies
This program is sponsored by the Medical College of Wisconsin and supported by the National Marrow Donor Program.

12:30 p.m. - 4:30 p.m. • Orange County Convention Center – Room 330 D-G

Speakers:

• Dennis Confer, MD, National Marrow Donor Program, Minneapolis, MN
• Stephen Forman, MD, City of Hope National Medical Center, Duarte, CA
• Daniel Weisdorf, MD, University of Minnesota, Minneapolis, MN
• Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA
• Patrick Beatty, MD, PhD, Montana Cancer Specialists, Missoula, MT
• J. Douglas Rizzo, MD, MS, Medical College of Wisconsin, Milwaukee, WI

This symposium will explore practical consideration for post-transplant care in key areas, including strategies for related versus unrelated donor transplants and cord blood recipients. Using case studies, a transplanter and a non-transplanter will provide their perspectives for care once a patient leaves the transplant center. They will discuss routine monitoring, benign signs and symptoms that should be addressed, and emergency presentation cases. The role of clinical trials will be addressed.

For more information, contact Renee Ryan, National Marrow Donor Program.

Phone: 612-884-8430
Fax: 612-627-5877
E-mail: rryan@nmdp.org

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Dennis Confer indicated no conflicts of interest.
• Dr. Stephen Forman indicated no conflicts of interest.
• Dr. Daniel Weisdorf: research support from AnorMED, Merck, Amgen, Genzyme, SuperGen, and Ligand; advisory board honoraria for Genzyme, Pharmion, and Schering-Plough.
• Dr. Stephanie Lee indicated no conflicts of interest.
• Dr. Patrick Beatty indicated no conflicts of interest.
• Dr. J. Douglas Rizzo indicated no conflicts of interest.

Challenges in the Management of Thrombosis: Role of Low Molecular Weight Heparins and Newer Anticoagulants in Medically Ill and Cancer Patients
This program is sponsored by Loyola University Medical Center and supported by Sanofi-Aventis Inc.

12:30 p.m. - 4:30 p.m. • Orange County Convention Center – Room 314

Speakers:

• Debra Hoppensteadt, PhD, Loyola University Medical Center, Chicago, IL
• Frederick Rickles, MD, Federation of American Societies for Experimental Biology, Bethesda, MD
• Craig Kessler, MD, Georgetown University Medical Center, Washington, DC
• Ajay Kakkar, MBBS, PhD, FRCS, Barts and The London School of Medicine and Dentistry, London, United Kingdom
• David G. Sherman, MD, University of Texas Health Science Center, San Antonio, TX
• Russell Hull, MD, University of Calgary, Foothills Hospital, Calgary, Alberta, Canada
• F.A. Anderson, PhD, University of Massachusetts Medical School, Worchester, MA

This symposium was developed to provide a comprehensive review of the pathogenesis of cancer-associated thrombotic and vascular disorders and their management with low molecular weight heparins (LMWHs). In addition, this program will also address the impact of extended/long-term medical illnesses on thrombotic and vascular complications and their potential relevance to occult malignancy. The role of LMWHs will be discussed by providing an objective review of the newer clinical trials in malignancy-related thrombosis.

For more information, contact Debra Hoppensteadt, PhD, Loyola University Medical Center.

Phone: 708-216-4625
Fax: 708-216-6660
E-mail: dhoppen@lumc.edu

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Debra Hoppensteadt indicated no conflicts of interest.
• Dr. Frederick Rickles: consultant for Pfizer, Sanofi-Aventis, and Bristol-Myers Squibb.
• Dr. Craig Kessler: grants/research support from, and a consultant and speakers bureau member for, Sanofi-Aventis; consultant for Pfizer and GlaxoSmithKline.
• Dr. Ajay Kakkar: grants/research support from, and a consultant for, Sanofi-Aventis.
• Dr. David G. Sherman: grants/research support from, and a consultant for, Sanofi-Aventis.
• Dr. Russell Hull: consultant for GlaxoSmithKline, Wyeth Pharmaceuticals, Pfizer, Leo Pharma Inc., Bayer, and Sanofi-Aventis.
• Dr. F.A. Anderson: grants/research support from, and a consultant for, Sanofi-Aventis.

Updates in CLL: Prognostic Markers and Their Implication for Treatment Strategies
This program is sponsored by the Center for Biomedical Continuing Education (CBCE) and supported by Mayne Pharma Inc.

12:30 p.m. - 4:30 p.m. • Rosen Plaza Hotel – Grand Ballroom A

Speakers:

• Michael J. Keating, MBBS, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• William G. Wierda, MD, PhD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Daniel Catovsky, MD, Institute of Cancer Research, London, United Kingdom
• Steven T. Rosen, MD, FACP, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
• Mark A. Weiss, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
• Peter Dreger, MD, PhD, Medizinische Klinik und Poliklinik V, Heidelberg, Germany
• Emili Montserrat, MD, Hospital Clinic, University of Barcelona, Barcelona, Spain
• William Plunkett, PhD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Neil E. Kay, MD, Mayo Clinic, Rochester, MN

This symposium will address how prognostic markers can be utilized when determining treatment options for your patients and assess currently available treatment approaches for your patients with CLL. The speakers will evaluate the rationale for molecular monitoring of patients with CLL following a clinical response. The safety and efficacy of new approaches for the treatment of patients with CLL will be compared and contrasted.

For more information, contact Michelle Smith, Center for Biomedical Continuing Education (CBCE).

Phone: 972-692-2056
Fax: 972-929-1901
E-mail: msmith@thecbce.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Michael J. Keating: consulting fees and honoraria for, and contracted research from, Genentech and Berlex.
• Dr. William G. Wierda: contracted research from Berlex, Sanofi-Aventis, and Genitope.
• Dr. Daniel Catovsky: consultant for Schering and Roche.
• Dr. Steven T. Rosen: consultant for Allos, Berlex, Biocryst, Celgene, CTI, Genentech, Genta, Ligand, Lilly, Merck, Supergen, and Wyrth; clinical trial grants from Berlex, Celgene, and Wyeth; honoraria from Celgene, Genentech, and Ligand.
• Dr. Mark A. Weiss: honoaria from Astellas Pharmaceuticals.
• Dr. Peter Dreger: honoraria from Schering and Roche.
• Dr. Emili Montserrat indicated no conflicts of interest.
• Dr. William Plunkett indicated no conflicts of interest.
• Dr. Neil E. Kay: contracted research for SuperGen and Berlex.

6:00 p.m. - 10:00 p.m.

Beyond Blood: Setting Our Sights on New Horizons in Gaucher Disease – Brain, Bones, and Biomarkers
This program is sponsored by Medical Education Resources (MER) and supported by Actelion Pharmaceuticals.

6:00 p.m. - 10:00 p.m. • Orange County Convention Center – Room 330 D-G

Speakers:

• Atul B. Mehta, MD, Royal Free Hospital and University College, London School of Medicine, London, United Kingdom
• Marc C. Patterson, MD, FRACP, Columbia University College of Physicians and Surgeons, New York, NY
• Gregory M. Pastores, MD, New York University, New York, NY
• Derralynn Hughes, MD, PhD, Royal Free and University College Medical School, London, United Kingdom
• Mario Maas, MD, Academic Medical Center, University of Amsterdam, Amsterdam , Netherlands
• Hans Aerts, PhD, University of Amsterdam, Amsterdam, Netherlands

This symposium will present new concepts in Gaucher disease beyond the current clinical paradigm, based on state-of-the-art multidisciplinary research exploring emerging biomarkers, and novel neurologic and bone disease processes.

For more information, contact Debbie DiRago, Concepts in Medicine.

Phone: 212-532-0700
Fax: 212-532-0026
E-mail: ddirago@conceptsinmedicine.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Atul B. Mehta indicated no conflicts of interest.
• Dr. Marc C. Patterson: research support from, and a consultant for, Actelion.
• Dr. Gregory M. Pastores: research support from Genzyme, Shire Pharmaceuticals Group, BioMarin, Actelion, and Amicus.
• Dr. Derralynn Hughes: research support from, a consultant for, and a speakers bureau member of, Actelion.
• Dr. Mario Maas indicated no conflicts of interest.
• Dr. Hans Aerts indicated no conflicts of interest.

Emerging Antibody-Based Therapies for Lymphoid Malignancies
This program is sponsored by Physicians Education Resource and supported by Biogen Idec Pharmaceuticals.

6:00 p.m. - 10:00 p.m. • Peabody Orlando Hotel – Florida Room

Speakers:

• Peter McLaughlin, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Anas Younes, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Jane Winter, MD, Feinberg School of Medicine, Chicago, IL
• Martin Glennie, MD, Southampton General Hospital, Southampton, United Kingdom
• Francisco Hernandez, MD, Roswell Park Cancer Institute, Buffalo, NY
• Kristie Blum, MD, The Ohio State University, Columbus, OH
• Bertrand Coiffier, MD, Hospices Civils de Lyon and University Claude Bernard, Lyon, France

Monoclonal antibody therapy has revolutionized the treatment of lymphoma. This symposium will be an overview of where monoclonal antibody therapies have brought us to today, what new agents we will use in the near future, and how scientific understanding will be used to optimize the NHL and CLL regimens of tomorrow.

For more information, contact Susanne Blassingille, Physicians Education Resource.

Phone: 214-367-3481
Fax: 214-367-3303
E-mail: sus.blassingille@pergrouplp.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Peter McLaughlin: consultant to Millennium Pharmaceuticals; speakers bureau member for Health Science Communications and CoMed Communications; research support from Berlex, Biogen Idec Pharmaceuticals, Genentech, Schering-Plough, Integrated Therapeutics, OSI Pharmaceuticals, and Millennium Pharmaceuticals.
• Dr. Anas Younes: speakers bureau member for Genentech and Biogen Idec; research funding from Genentech, Biogen Idec, Seattle Genetics, and MethylGene.
• Dr. Jane Winter: research funding from Biogen Idec.
• Dr. Martin Glennie: employee of, and stock holdings in, Genmab AS; consultant for Medarex.
• Dr. Francisco Hernandez: consultant for Wyeth; on the speakers bureau for Genentech.
• Dr. Kristie Blum indicated no conflicts of interest.
• Dr. Bertrand Coiffier: consultant to Roche; speakers bureau for Roche, Genentech, Johnson and Johnson, Biogen, and Sanofi-Aventis; research funding from Roche and Genentech.

Emerging Paradigms for the Management of CML: A 2006 Perspective
This program is sponsored by Physicians Education Resource and supported by Bristol-Myers Squibb.

6:00 p.m. - 10:00 p.m. • Orange County Convention Center – Valencia A-B

Speakers:

• John Goldman, DM, National Institutes of Health, Bethesda, MD
• Andreas Hochhaus, MD, Ruprecht-Karls-Universität, Heidelberg, Germany
• Moshe Talpaz, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Neil Shah, MD, PhD, University of Southern California – Los Angeles, Los Angeles, CA
• Michael Deininger, MD, PhD, Oregon Health and Science University, Portland, OR
• Jerald Radich, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
• Francois Guilhot, MD, Hopital Jean Bernard, CHRU La Miletrie, Poitiers, France

The purpose of this symposium is to update physicians on the current status of treatments for CML, including a review of the standards of care in the age of targeted inhibitors and strategies for optimizing response in subsets of patients with early or advanced disease with second generation ABL kinase inhibitors.

For more information, contact Susanne Blassingille, Physicians Education Resource.

Phone: 214-367-3481
Fax: 214-367-3303
E-mail: sus.blassingille@pergrouplp.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. John Goldman: consultant to Novartis.
• Dr. Andreas Hochhaus: consultant to Novartis and Bristol-Myers Squibb; research funding from Novartis, Bristol-Myers Squibb, and Schering-Plough.
• Dr. Moshe Talpaz: research funding from Bristol-Myers Squibb; consultant/advisory board member for Bristol-Myers Squibb and Novartis Oncology.
• Dr. Neil Shah: research funding from Bristol-Myers Squibb Oncology.
• Dr. Michael Deininger: consultant to Novartis and Bristol-Myers Squibb.
• Dr. Jerald Radich: consultant to Novartis, Bristol-Myers Squibb, and Vulcan Capital; research funding from Novartis and Bristol-Myers Squibb.
• Dr. Francois Guilhot: consultant to Bristol-Myers Squibb.

Current and Future Perspectives on the Treatment of Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
This program is sponsored by the Rush University Medical Center and supported by Cephalon.

6:00 p.m. - 10:00 p.m. • Rosen Centre Hotel – Grand Ballroom D-E

Speakers:

• Fernando Cabanillas, MD, Hospital Auxilio Mutuo, San Juan, PR
• Stephanie Gregory, MD, Rush Medical Center, Chicago, IL
• Thomas Witzig, MD, Mayo Clinic, Rochester, MN
• John Leonard, MD, Weill Cornell Cancer Care Center, New York, NY
• Mathias Rummel, MD, University of Frankfurt Medical School, Frankfurt, Germany
• Jonathan Friedberg, MD, University of Rochester, Rochester, NY

This symposium will cover the treatment of relapsed/refractory disease, incorporating the European experience in treating these patients, while also introducing the U.S. clinical experience with some of the newer agents, in an endeavor to make hematologists and oncologists familiar with the latest emerging therapeutic modalities for non-Hodgkin lymphoma.

For more information, contact Robin Simak, Jonathan Wood and Associates.

Phone: 201-594-0400
Fax: 201-594-0409
E-mail: rsimak@jwoodassoc.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Fernando Cabanillas indicated no conflicts of interest.
• Dr. Stephanie Gregory: research grants from Biogen Idec, Celgene, Genentech, Amgen, Millennium, Ortho Biotech, GlaxoSmithKline, Ligand, Berlex, and Merck; educator and consultant for Biogen Idec, Genentech, Ortho Biotech, and GlaxoSmithKline; consultant for Amgen.
• Dr. Thomas Witzig: research support from Biogen Idec.
• Dr. John Leonard: grant/research support from Biogen Idec, Genentech, Seattle Genetics, Millennium Pharmaceuticals, Immunomedics, GlaxoSmithKline, and Cephalon; consultant for Biogen Idec, Genentech, Millennium Pharmaceuticals, GlaxoSmithKline, Wyeth, Berlex, and Cougar Biotechnology; speakers bureau for Biogen Idec, Genentech, Millennium Pharmaceuticals, and GlaxoSmithKline.
• Dr. Mathias Rummel indicated no conflicts of interest.
• Dr. Jonathan Friedberg: research support from Cephalon.

Targeting Apoptosis: The Next Generation of Cancer Therapy
This program is sponsored by Veritas Institute for Medical Education Inc. and supported by Genta Inc.

6:00 p.m. - 10:00 p.m. • Rosen Plaza Hotel – Grand Ballroom C

Speakers:

• Bruce Cheson, MD, Georgetown University Hospital, Washington, DC
• Dennis A. Carson, MD, University of California – San Diego, La Jolla, CA
• Margaret Shipp, MD, Harvard Medical School, Boston, MA
• Anthony W. Tolcher, MD, The Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX
• Owen O’Connor, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY

This symposium will discuss the impact of apoptotic defects on the pathophysiology and progression of CLL and the development of resistance to therapy. It will evaluate uses of new technologies for determining gene signatures in order to individualize therapy for patients with CLL.

For more information, contact Lauren Cirangle, NeoHealth Inc.

Phone: 201-288-6262, ext. 3233
Fax: 201-727-1725
E-mail: lauren.cirangle@neohealth.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Bruce Cheson indicated no conflicts of interest.
• Dr. Dennis Carson: consultant for Edwards Lifesciences and MedImmune; ownership interest in Dynavax.
• Dr. Margaret Shipp: consultant for Eli Lilly and Abbott.
• Dr. Anthony Tolcher: consultant for Genta Aventis, Genentech, and AstraZeneca; contracted research with Genta Aventis.
• Dr. Owen O’Connor indicated no conflicts of interest.

Advances in the Management of Venous Thromboembolic Disorders Associated with Cancer and the Antiphospholipid Syndrome
This program is sponsored by McMaster University and supported by GlaxoSmithKline.

6:00 p.m. - 10:00 p.m. • Rosen Plaza Hotel – Grand Ballroom A

Speakers:

• John Kelton, MD, FRCPC, McMaster University, Hamilton, Ontario, Canada
• Mark A. Crowther, MD, MSc, McMaster University and St. Joseph’s Hospital, Hamilton, Ontario, Canada
• Bruce Davidson, MD, MPH, University of Washington School of Medicine, Seattle, WA
• Lawrence Rice, MD, Baylor College of Medicine, Houston, TX
• Kathryn Hassell, MD, University of Colorado Health Sciences Center, Denver, CO
• Thomas L. Ortel, MD, PhD, Duke University Medical Center, Durham, NC  
• Agnes Lee, MD, MSc, Michael G. DeGroote School of Medicine, McMaster Uninversity, Hamilton, Ontario, Canada

This symposium will describe and differentiate the causes and treatments of thrombocytopenia in different patient populations, including surgical patients, patients with cancer, and patients with APS.

For more information, contact Audrie Tornow, Continuing Edge, a division of Global Edge Inc.

Phone: 212-293-2310
Fax: 212-293-2316
E-mail: atornow@globaledge-us.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. John Kelton: consultant for GlaxoSmithKline.
• Dr. Mark A. Crowther: grant/research support and consultant fees from, and speakers bureau member for,Sanofi-Aventis, Leo Laboratories, and Pfizer; speakers bureau for Novo Nordisk.
• Dr. Bruce Davidson: grant/research support and consultation fees from Bayer, Sanofi-Aventis, and Bristol-Myers Squibb.
• Dr. Lawrence Rice: grant/research support and consultation fees from, and speakers bureau member for, GlaxoSmithKline; speakers bureau for Sanofi-Aventis, Berlex, and The Medicine Company; consultation fees from Berlex, and The Medicine Company.
• Dr. Kathryn Hassell: speakers bureau for GlaxoSmithKline, Sanofi-Aventis, and Organon; grant research support from GlaxoSmithKline; consultation fees from Organon and Sanofi-Aventis.
• Dr. Thomas L. Ortel: grant/research support from Pfizer; financial/material interest in ZyCare.
• Dr. Agnes Lee: grant/research support from Pfizer and Leo Pharma; consultation fees from Pfizer, Merck, AstraZeneca, and Sanofi-Aventis.

Innovative Strategies for Treating Myeloma: Case Discussions
This program is sponsored by the Institute for Continuing Healthcare Education and supported by the International Myeloma Foundation.

6:00 p.m. - 10:00 p.m. • Orange County Convention Center – Room 311

Speakers:

• Brian G.M. Durie, MD, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA
• Jean-Luc Harousseau, MD, University Hospital Nantes, Nantes, France
• S. Vincent Rajkumar, MD, Mayo Clinic College of Medicine, Rochester, MN
• Jesus San Miguel, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain
• Bart Barlogie, MD, PhD, University of Arkansas for Medical Sciences, Little Rock, AR
• Mario Boccadoro, MD, University of Torino, Torino, Italy

This symposium will provide a forum for discussion of the latest treatment options for patients with multiple myeloma. Panel members will review case studies addressing new treatment approaches and identify the role of newer agents with respect to existing therapies in multiple myeloma for a newly diagnosed patient, high-risk patient, and a relapsed patient.

For more information, contact Marisa Putnam, Institute for Continuing Healthcare Education.

Phone: 215-446-8088
Fax: 215-592-9085
E-mail: mputnam@iche.edu

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Brian G.M. Durie:honoraria and research grants from Millennium Pharmaceuticals and Celgene; speakers bureau for Millennium Pharmaceuticals; honoraria from Kyphon.
• Dr. Jean-Luc Harousseau:honoraria from, and advisory activities for, Millennium Pharmaceuticals and Pharmion; speakers bureau for Ortho Biotech and Amgen; research funding from Celgene, Ortho Biotech, and Millennium Pharmaceuticals.
• Dr. S. Vincent Rajkumar:research grants from Celgene and Millennium Pharmaceuticals.
• Dr. Jesus San Miguel: honoraria related to speaker bureau activities from Johnson and Johnson, Millennium Pharmaceuticals, and Pharmion; honoraria related to scientific advisory boards of Celgene, Johnson and Johnson, Millennium Pharmaceuticals, and Pharmion.
• Dr. Bart Barlogie:honoraria related to formal advisory and speaker bureau activities from Celgene and Millennium Pharmaceuticals.
• Dr. Mario Boccadoro indicated no conflicts of interest.

New Therapeutic Targets in Hematologic Malignancies
This program is sponsored by Physicians Education Resource and supported by Merck Oncology.

6:00 p.m. - 10:00 p.m. • Orange County Convention Center – Room 224 A-B-E-F

Speakers:

• Kapil Bhalla, MD, H. Lee Moffit Cancer Center and Research Institute, Tampa, FL
• Madeleine Duvic, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Steven Horwitz, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
• Ghulam Mufti, DM, FRCP, FRCPath, King’s College Hospital, London, United Kingdom
• Thomas Look, MD, Dana-Farber Cancer Institute, Boston, MA
• Michael Mauro, MD, Oregon Health and Science University, Portland, OR
• Thomas Patterson, MD, University of Texas Health Science Center, San Antonio, TX

The objective of this symposium will be to review the cellular processes which underlie the development of hematologic malignancies as a platform for discussion about novel therapeutic agents which reverse these abnormalities. The practical side of cancer therapeutics, including management of infection and standard of care for these diseases, will be discussed as well. The symposium will be relevant to physicians who treat patients with leukemia or lymphoma, as well as many solid tumors.

For more information, contact Susanne Blassingille, Physicians Education Resource.

Phone: 214-367-3481
Fax: 214-367-3303
E-mail: sus.blassingille@pergrouplp.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Kapil Bhalla: research funding from Novartis Pharmaceuticals.
• Dr. Madeleine Duvic: on the advisory board of, and research funding from, Merck; research grants from Ligand, BioCryst, Therakos, Biogen, Gloucester Pharmaceuticals, Seattle Genetics, and Celgene.
• Dr. Steven Horwitz: consultant for Genentech, Merck, Therakos, and Gloucester Pharmaceuticals.
• Dr. Ghulam Mufti indicated no conflicts of interest.
• Dr. Thomas Look: consultant for OncoMed; research finding from Merck.
• Dr. Michael Mauro indicated no conflicts of interest.
• Dr. Thomas Patterson: consultant for Astellas, Merck, Pfizer, Schering-Plough, Affinium Pharmaceuticals, Basilea, Diversa, Eisai, J. Uriach and CIA S.A., Enzon, MediciNova, Microbia, Nektar Therapeutics, Rib-X Pharmaceuticals, Human Genome Sciences, and CoGenesys; on the speakers bureau of Merck, Astellas, Pfizer, and Schering-Plough; research funding from Merck, Astellas, Pfizer, Schering-Plough, and Enzon.

The Evolution of Multiple Myeloma Treatment: Emerging Strategies
This program is sponsored by the Center for Bio-Medical Communications Inc. (CBC) and supported by the Multiple Myeloma Research Foundation (MMRF).

6:00 p.m. - 10:00 p.m. • Rosen Centre Hotel – Grand Ballroom A-B

Speakers:

• Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA
• Sagar Lonial, MD, Emory Winship Cancer Institute, Atlanta, GA
• Michel Attal, MD, PRD, Hospital Purpan, Toulouse, France
• Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA
• Meletios A. Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece

In this innovative session, we will highlight the most recent advances in treating multiple myeloma, discuss novel therapies that are in development, and discuss the likely origin of the next significant advance in the treatment of this progressive disease.

For more information, contact Regina Janesko, Center for Bio-Medical Communication, Inc. (CBC).

Phone: 201-883-5185
Fax: 201-342-7555
E-mail: rjanesko@cbcbiomed.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Kenneth Anderson: grant/research support from, and consultant for, Celgene, Millennium Pharmaceuticals, and Novartis; speakers bureau for Celgene and Millennium Pharmaceuticals.
• Dr. Sagar Lonial: grant/research support from, and consultant for, Millennium Pharmaceuticals; consultant for Celgene.
• Dr. Michel Attal indicated no conflicts of interest.
• Dr. Paul Richardson: advisory board and speakers bureau for Celgene and Millennium Pharmaceuticals.
• Dr. Meletios A. Dimopoulos: consultant and scientific advisor for Celgene and Ortho Biotech.

The Evolution of Targeted Therapies for the Treatment of Hematologic Malignancies: Incorporating Novel Agents into the Treatment Paradigm
This program is sponsored by the Health Science Center for Continuing Medical Education and supported by Novartis Oncology Office of Grants and Education.

6:00 p.m. - 10:00 p.m. • Orange County Convention Center – Hall WF 3, 4, 5

Speakers:

• Francis J. Giles, MD, MRCPI, MRCPath, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Timothy Hughes, MD, MBBS, Royal Adelaide Hospital, Adelaide, South Australia, Australia
• Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
• Oliver Ottman, MD, Johann Wolfgang Goethe University, Frankfurt, Germany

This symposium reviews the latest advancements for the treatment of CML by reporting novel findings on ongoing second generation ABL kinase inhibitor trials and patient management strategies including patient monitoring/treatment dosing, and identification of appropriate treatments for different patient types.

For more information, James New, Health Science Center for Continuing Medical Education.

Phone: 212-849-7826
Fax: 212-741-7728
E-mail: jnew@health-ny.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Francis J. Giles: research grants from Amgen, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Structural Genomix, and Kosan.
• Dr. Timothy Hughes: grants/research support from Bristol-Myers Squibb; grants/research support and a speaker honorarium from Novartis.
• Dr. Daniel DeAngelo: speakers bureau member for Cell Therapeutics, Novartis Oncology, and Celgene.
• Dr. Oliver Ottman: honoraria from Bristol-Myers Squibb, Novartis, Merck, Pharmion, and Vion; grants/research support from Novartis.

Optimizing Therapy of Multiple Myeloma: Role of Anthracyclines and Other Novel Agents
This program is sponsored by Physicians Education Resource and supported by Ortho Biotech.

6:00 p.m. - 10:00 p.m. • Peabody Orlando Hotel – Orlando Room

Speakers:

• Raymond Alexanian, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Mohamad Hussein, MD, Cleveland Clinic Foundation, Cleveland, OH
• Alberto Gabizon, MD, Shaare Zedek Medical Center, Jerusalem, Israel
• Robert Rifkin, MD, Rocky Mountain Cancer Center, Denver, CO
• Robert Orlowski, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC
• Asher Chanan-Khan, MD, Roswell Park Cancer Institute, Buffalo, NY
• Peter Leif Bergsagel, MD, Mayo Clinic Scottsdale, Scottsdale, AZ

The objective of this symposium will be to educate physicians about regimens which include liposomal anthracyclines in both front-line stem cell sparing regimens and relapsed patients. Special attention will be given to the practical considerations of the management of multiple myeloma, including safety and management of adverse effects.

For more information, contact Susanne Blassingille, Physicians Education Resource.

Phone: 214-367-3481
Fax: 214-367-3303
E-mail: sus.blassingille@pergrouplp.com

Speaker Disclosures:
The speakers for this symposium have indicated the following possible conflicts of interest.

• Dr. Raymond Alexanian: research funding from Celgene.
• Dr. Mohamad Hussein: consultant for PDL BioPharma, Gerson Lehrman Group Healthcare Council, and Kyphon; research funding from Novartis, Amgen, Cell Therapeutics Inc., Ortho Biotech, ALZA, Kyphon, Celgene, PDL BioPharma, Tibotec, and the National Cancer Institute.
• Dr. Alberto Gabizon: research funding and royalty payments from Johnson and Johnson.
• Dr. Robert Rifkin: speakers bureau member for Celgene and Millennium Pharmaceuticals.
• Dr. Robert Orlowski indicated no conflicts of interest.
• Dr. Asher Chanan-Khan: on the speakers bureaus of Ortho Biotech and Millennium Pharmaceuticals; research funding from Ortho Biotech.
• Dr. Peter Leif Bergsagel indicated no conflicts of interest.